Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H23N3O4S.ClH |
| Molecular Weight | 377.887 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN1CCC[C@H]1CNC(=O)C2=C(OC)C=CC(=C2)S(N)(=O)=O
InChI
InChIKey=PFHZICSPLHQCDZ-MERQFXBCSA-N
InChI=1S/C15H23N3O4S.ClH/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2;/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21);1H/t11-;/m0./s1
| Molecular Formula | C15H23N3O4S |
| Molecular Weight | 341.426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://medind.nic.in/daa/t07/i2/daat07i2p144.pdf | http://www.druginfosys.com/drug.aspx?drugcode=1180&type=1
Curator's Comment: Description was created based on several sources, including
http://medind.nic.in/daa/t07/i2/daat07i2p144.pdf | http://www.druginfosys.com/drug.aspx?drugcode=1180&type=1
Levosulpiride [RV 12309, L-sulpiride, levosulpride, Dislep® 25, Levopride®, Levopraid®] is a potent dopamine D2 receptor blocker that was originated by Ravizza Farmaceutici (now AbbVie). Levosulpiride is the levo enantiomer of sulpiride. The levo enantiomer shows better/similar pharmacological actions and lower incidence of toxic effects than both dextro as well as the racemic forms of the drug. Levosulpiride is marketed in Italy and South Korea, and is possibly available elsewhere in Europe and Asia. Levosulpiride does not appear to be available in North America. Levosulpiride is available as 25mg tablets, drops and in ampoules for parenteral administration. Generic versions of levosulpiride also appear to be available in some countries. Levosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
51.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Levopraid Approved UseLevosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo. |
|||
| Primary | Unknown Approved UseLevosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo. |
|||
| Primary | Levopraid Approved UseLevosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo. |
|||
| Primary | Levopraid Approved UseLevosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo. |
|||
| Primary | Unknown Approved UseLevosulpiride is primarily indicated in conditions like Anxiety, Depression, Gastro-esophageal reflux disease, Irritable bowel syndrome, Schizophrenia, Tourette's syndrome, dyspeptic syndrome, essential cephalgia, and can also be given in adjunctive therapy as an alternative drug of choice in Peptic ulcer, Vertigo. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. | 1992 Apr 10 |
|
| A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. | 1993 Dec |
|
| Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. | 1994 Jan |
|
| Expression and pharmacological characterization of the human D3 dopamine receptor. | 1994 Jan |
|
| A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis. | 1995 Sep-Oct |
|
| Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. | 1996 Dec |
|
| Side-effects of benzamide derivatives. | 1997 Jan |
|
| 5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract. | 2003 Apr |
|
| Improvement and validation of a liquid chromatographic method for the determination of levosulpiride in human serum and urine. | 2003 Nov 5 |
|
| Improvement of vestibular compensation by Levo-sulpiride in acute unilateral labyrinthine dysfunction. | 2004 Apr |
|
| Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. | 2004 Apr |
|
| Delayed Gastric Emptying in Functional Dyspepsia. | 2004 Aug |
|
| Type 1 (insulin-dependent) diabetes mellitus and gastric emptying: role of blood glucose concentration and dopamine D2 receptors. | 2004 Feb |
|
| Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. | 2004 Feb 15 |
|
| Development of HPLC method for the determination of levosulpiride in human plasma. | 2004 Jun 29 |
|
| Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. | 2004 Mar |
|
| Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers. | 2004 Mar |
|
| The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy. | 2004 Nov 20 |
|
| Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levosulpiride in human plasma. | 2004 Oct 5 |
|
| BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. | 2005 |
|
| Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol. | 2005 Feb |
|
| [Two cases of tardive Tourette syndrome]. | 2006 |
|
| Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. | 2006 Feb 28 |
|
| Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes. | 2006 Mar |
|
| Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a systematic review of randomized controlled trials. | 2007 |
|
| [The effect of sulpirid in treatment of patients with gastric and duodenal erosions and ulcers]. | 2007 |
|
| [Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease]. | 2007 |
|
| Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. | 2007 Mar |
|
| Clinical outcome of rumination syndrome in adults without psychiatric illness: a prospective study. | 2007 Nov |
|
| Triple reuptake inhibitors: the next generation of antidepressants. | 2008 Dec |
|
| [Major gastrointestinal syndromes (2): dyspepsia or syndrome of the upper digestive system related with food (2)]. | 2008 Jul-Sep |
|
| Long-term Ultrasonographic Follow-up Study of Gastric Motility in Patients with Functional Dyspepsia. | 2008 Mar |
|
| Triple reuptake inhibitors: a premise and promise. | 2008 Sep |
|
| Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine. | 2009 |
|
| Levosulpiride-induced resting orolingual tremor. | 2009 Aug 15 |
|
| Rapid quantification of levosulpiride in human plasma using RP-HPLC-MS/MS for pharmacokinetic and bioequivalence study. | 2009 Dec |
|
| Combination therapy of levosulpiride and lamotrigine associated with tardive dyskinesia. | 2009 Feb |
|
| Teratogenicity and hyperprolactinemia. | 2009 Jan |
|
| [Efficiacy of combined eglonil and avestin administration for pharmacocorrection of depressive disorders in women with hypoestrogenic syndrome]. | 2009 Jul-Aug |
|
| Determination of metoclopramide in human plasma using hydrophilic interaction chromatography with tandem mass spectrometry. | 2009 Jun 15 |
|
| Associations among hair loss, oral sulfur-containing gases, and gastrointestinal and metabolic linked diseases in Japanese elderly men: pilot study. | 2009 Mar 13 |
|
| Gastroparesis: current concepts and management. | 2009 Sep |
|
| Diabetes mellitus and drug-induced Parkinsonism: a case-control study. | 2009 Sep 15 |
|
| Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. | 2010 |
|
| Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. | 2010 Aug 11 |
|
| Liquid chromatography-tandem mass spectrometry quantification of levosulpiride in human plasma and its application to bioequivalence study. | 2010 Aug 15 |
|
| A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism. | 2010 Jan |
|
| Pharmacotherapy for gastroparesis: an attempt to evaluate a safer alternative. | 2010 Oct |
|
| [Levosulpiride in the management of functional dyspepsia and delayed gastric emptying]. | 2010 Oct |
|
| Levosulpiride in premature ejaculation. | 2010 Oct-Dec |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:39:18 GMT 2023
by
admin
on
Sat Dec 16 11:39:18 GMT 2023
|
| Record UNII |
3400N2ZP5P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3400N2ZP5P
Created by
admin on Sat Dec 16 11:39:18 GMT 2023 , Edited by admin on Sat Dec 16 11:39:18 GMT 2023
|
PRIMARY | |||
|
77111-58-1
Created by
admin on Sat Dec 16 11:39:18 GMT 2023 , Edited by admin on Sat Dec 16 11:39:18 GMT 2023
|
PRIMARY | |||
|
121490096
Created by
admin on Sat Dec 16 11:39:18 GMT 2023 , Edited by admin on Sat Dec 16 11:39:18 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
